Ventripoint Diagnostics Ltd. (VPTDF) 0.0700 $VPTDF
IIROC Trade Resumption - VentriPoint Diagnostics Ltd.
Newsfile Corp - Mon Mar 10, 8:35AM CDT
Trading resumes in:
FDA Clears Ventripoint VMS(TM) Heart Analysis System for Use in Patients with Pulmonary Arterial Hypertension
Marketwire - Mon Mar 10, 7:24AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint") (TSX VENTURE: VPT) announces that the US Food and Drug Administration (FDA) has cleared the VMS(TM) heart analysis system to be an adjunct to all existing 2D ultrasound imaging devices to allow computation of the 3D volume and ejection fraction of the right heart in patients with Pulmonary Arterial Hypertension (PAH).
IIROC Trade Halt - VentriPoint Diagnostics Ltd.
Newsfile Corp - Fri Mar 07, 2:55PM CST
The following issues have been halted by IIROC:
Oculus Innovative Sciences, Inc. to Raise $1.35 Million in Registered Direct Offering
GlobeNewswire - Fri Feb 21, 9:00PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced today that it has entered into definitive agreements with two life sciences-focused institutional investors for the sale of 450,620 units, consisting of shares of common stock, and Series A and Series B warrants, at a per unit price of $3.00 per share. The total amount sold consisted of a combination of: (1) 450,620 shares of its common stock; (2) Series A warrants to purchase up to 450,620 shares of common stock at an exercise price of $3.00 per share and a term of five years; and (3) Series B warrants to purchase up to 1,400,000 shares of common stock at an exercise price of $3.63 per share. The Series B warrants are not exercisable for six months following the closing of the IPO and have a term of 18 months. The Series B warrants have not vested and will not vest until the completion of the initial public offering (IPO) by the company's subsidiary, Ruthigen, Inc. The Series B warrants terminate on March 31, 2014, if the Ruthigen IPO has not occurred by that date.
Ventripoint Announces 510(k) Submission for VMS Heart Analysis System and Issuance of Shares for Debt
Marketwire - Thu Jan 23, 6:01AM CST
Ventripoint Diagnostics Ltd. (TSX VENTURE: VPT) is pleased to announce that it has submitted to the US Federal Drug Administration ("the Agency") a new 510(k) for clearance for the VMS(TM) heart analysis system for use in Pulmonary Arterial Hypertension (PAH).
Yieldex Wraps Up 2013 With 1.5 Trillion Impressions
Marketwire - Thu Dec 19, 8:30AM CST
Yieldex, the leading provider of inventory and revenue management solutions for digital publishers, today announced that 1.5 trillion ad impressions have been analyzed via the YieldEdge platform this year, demonstrating that companies are increasing their investment and reliance on big data analytics to grow their businesses.
Ventripoint Announces Regulatory Update for VMS(tm) Heart Analysis System
ACCESSWIRE - Fri Dec 13, 4:29PM CST
Seattle, Washington, December 13, 2013 - Ventripoint Diagnostics Ltd. (TSXV:VPT) (the Company or Ventripoint) is pleased to announce that the it has responded within the specified 30-day period to the non-substantially equivalent (NSE) letter received from the U.S. FDA on November 14, 2013, and has had numerous discussions with the FDA to identify the best and quickest pathway to obtain clearance for the VMS(TM) heart analysis system for use in Pulmonary Arterial Hypertension (PAH).
Ventripoint Announces Planned Response to FDA Notification and Expanded Sales Efforts Outside of the United States
ACCESSWIRE - Mon Nov 25, 3:11PM CST
** FDA has Invited the Company to Meet the Review Team **
Ventripoint Receives Response from FDA for Application of VMS (tm) for use in Pulmonary Arterial Hypertension
ACCESSWIRE - Fri Nov 15, 8:02AM CST
Seattle, Washington, November 15, 2013 - Ventripoint Diagnostics Ltd. ("Ventripoint") (TSXV:VPT) announces that the FDA has closed its review of the Company's 510(K) application for approval of the Ventripoint Medical System (VMS(TM)) for use in Pulmonary Arterial Hypertension (PAH). The FDA has found that despite achieving an average agreement between VMS and MRI results within the allowable 10% mean difference, the substantial equivalency was not sufficiently proven to warrant approval. The FDA stated that Ventripoint is welcome to submit a new 510(K) application with data that would show substantial equivalency.
IIROC: Halt; VentriPoint Diagnostics Ltd.
Marketwire Canada - Fri Nov 15, 7:17AM CST
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants :
VentriPoint Diagnostics, Legend Gold and Black Iron Featured on Episode 18 of the Next Biggest Winner TV Show This Weekend
Marketwire - Thu Nov 14, 10:54AM CST
The Next Biggest Winner, a leading and nationally televised investment show focusing on small-cap and mid-cap companies, is pleased to announce Episode 18 will be airing across Canada this weekend.
Ventripoint Announces Increase and Closing Of Debenture Unit Private Placement
ACCESSWIRE - Tue Oct 22, 5:34PM CDT
Seattle, Washington, October 22, 2013 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation") (TSXV:VPT) is pleased to announce that it has increased its debenture unit placement from $300,000 to $500,000 and has completed its non-brokered private placement of debenture units of the Corporation previously announced on September 27, 2013 (the "Offering"). The Corporation issued $500,000 in $1,000 principal amounts of convertible non-secured debentures ("Debentures"), which shall mature three years from the date of issuance of the Debentures (the "Maturity Date"), and issued a total of 2,500,000 common share purchase warrants with an exercise price of $0.15 for a period of three years. The Debentures shall bear a 12% annual simple interest calculated on the principal amount, with any accrued but unpaid interest under the Debentures due and payable on the anniversary of the Debenture in either cash or Common Shares (at the option of the Corporation) with the number of Common Shares being determined by using the 10 day volume-weighted average price of the Common Shares on the TSX Venture Exchange on that date that is five days prior to the anniversary date (subject to the approval of the TSX Venture Exchange). The Debentures may be converted by the holder at any time following the date of issuance at a price of $0.10 per share and the Debentures may be repaid partially, or in full, by the Corporation to any or all of the subscribers at any time without penalty.
Ventripoint Announces Completion of Analysis of Pulmonary Arterial Hypertension Clinical Data and Submission to FDA
ACCESSWIRE - Mon Oct 07, 6:23AM CDT
Clinical Trial Achieved all the Primary Endpoints for Heart Analysis
Ventripoint Announces Closing of Private Placement
Marketwire - Mon Jul 29, 5:49PM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSX VENTURE: VPT) (OTCQX: VPTDF) announces that it has completed the second closing of the second of its two previously announced non-brokered private placements.
University of Chicago Publishes First Results Using Ventripoint Heart Analysis System in Pulmonary Arterial Hypertension in Prestigous Medical Journal
Marketwire - Thu Jul 25, 6:01AM CDT
Ventripoint Diagnostics (TSX VENTURE: VPT)(OTCQX: VPTDF) is pleased to announce that the cardiology group from the University of Chicago, led by Dr. Roberto Lang, has published a paper entitled "Three-Dimensional Modeling of the Right Ventricle from Two-Dimensional Transthoracic Echocardiographic Images: Utility of Knowledge-Based Reconstruction(i) in Pulmonary Arterial Hypertension" in the Journal of the American Society of Echocardiography, Volume 26, Issue 8, Pages 860-867, August 2013.
IIROC Trade Resumption - VentriPoint Diagnostics Ltd.
Newsfile Corp - Mon Mar 10, 8:35AM CDT
Trading resumes in:
FDA Clears Ventripoint VMS(TM) Heart Analysis System for Use in Patients with Pulmonary Arterial Hypertension
Marketwire - Mon Mar 10, 7:24AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint") (TSX VENTURE: VPT) announces that the US Food and Drug Administration (FDA) has cleared the VMS(TM) heart analysis system to be an adjunct to all existing 2D ultrasound imaging devices to allow computation of the 3D volume and ejection fraction of the right heart in patients with Pulmonary Arterial Hypertension (PAH).
IIROC Trade Halt - VentriPoint Diagnostics Ltd.
Newsfile Corp - Fri Mar 07, 2:55PM CST
The following issues have been halted by IIROC:
Oculus Innovative Sciences, Inc. to Raise $1.35 Million in Registered Direct Offering
GlobeNewswire - Fri Feb 21, 9:00PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced today that it has entered into definitive agreements with two life sciences-focused institutional investors for the sale of 450,620 units, consisting of shares of common stock, and Series A and Series B warrants, at a per unit price of $3.00 per share. The total amount sold consisted of a combination of: (1) 450,620 shares of its common stock; (2) Series A warrants to purchase up to 450,620 shares of common stock at an exercise price of $3.00 per share and a term of five years; and (3) Series B warrants to purchase up to 1,400,000 shares of common stock at an exercise price of $3.63 per share. The Series B warrants are not exercisable for six months following the closing of the IPO and have a term of 18 months. The Series B warrants have not vested and will not vest until the completion of the initial public offering (IPO) by the company's subsidiary, Ruthigen, Inc. The Series B warrants terminate on March 31, 2014, if the Ruthigen IPO has not occurred by that date.
Ventripoint Announces 510(k) Submission for VMS Heart Analysis System and Issuance of Shares for Debt
Marketwire - Thu Jan 23, 6:01AM CST
Ventripoint Diagnostics Ltd. (TSX VENTURE: VPT) is pleased to announce that it has submitted to the US Federal Drug Administration ("the Agency") a new 510(k) for clearance for the VMS(TM) heart analysis system for use in Pulmonary Arterial Hypertension (PAH).
Yieldex Wraps Up 2013 With 1.5 Trillion Impressions
Marketwire - Thu Dec 19, 8:30AM CST
Yieldex, the leading provider of inventory and revenue management solutions for digital publishers, today announced that 1.5 trillion ad impressions have been analyzed via the YieldEdge platform this year, demonstrating that companies are increasing their investment and reliance on big data analytics to grow their businesses.
Ventripoint Announces Regulatory Update for VMS(tm) Heart Analysis System
ACCESSWIRE - Fri Dec 13, 4:29PM CST
Seattle, Washington, December 13, 2013 - Ventripoint Diagnostics Ltd. (TSXV:VPT) (the Company or Ventripoint) is pleased to announce that the it has responded within the specified 30-day period to the non-substantially equivalent (NSE) letter received from the U.S. FDA on November 14, 2013, and has had numerous discussions with the FDA to identify the best and quickest pathway to obtain clearance for the VMS(TM) heart analysis system for use in Pulmonary Arterial Hypertension (PAH).
Ventripoint Announces Planned Response to FDA Notification and Expanded Sales Efforts Outside of the United States
ACCESSWIRE - Mon Nov 25, 3:11PM CST
** FDA has Invited the Company to Meet the Review Team **
Ventripoint Receives Response from FDA for Application of VMS (tm) for use in Pulmonary Arterial Hypertension
ACCESSWIRE - Fri Nov 15, 8:02AM CST
Seattle, Washington, November 15, 2013 - Ventripoint Diagnostics Ltd. ("Ventripoint") (TSXV:VPT) announces that the FDA has closed its review of the Company's 510(K) application for approval of the Ventripoint Medical System (VMS(TM)) for use in Pulmonary Arterial Hypertension (PAH). The FDA has found that despite achieving an average agreement between VMS and MRI results within the allowable 10% mean difference, the substantial equivalency was not sufficiently proven to warrant approval. The FDA stated that Ventripoint is welcome to submit a new 510(K) application with data that would show substantial equivalency.
IIROC: Halt; VentriPoint Diagnostics Ltd.
Marketwire Canada - Fri Nov 15, 7:17AM CST
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants :
VentriPoint Diagnostics, Legend Gold and Black Iron Featured on Episode 18 of the Next Biggest Winner TV Show This Weekend
Marketwire - Thu Nov 14, 10:54AM CST
The Next Biggest Winner, a leading and nationally televised investment show focusing on small-cap and mid-cap companies, is pleased to announce Episode 18 will be airing across Canada this weekend.
Ventripoint Announces Increase and Closing Of Debenture Unit Private Placement
ACCESSWIRE - Tue Oct 22, 5:34PM CDT
Seattle, Washington, October 22, 2013 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation") (TSXV:VPT) is pleased to announce that it has increased its debenture unit placement from $300,000 to $500,000 and has completed its non-brokered private placement of debenture units of the Corporation previously announced on September 27, 2013 (the "Offering"). The Corporation issued $500,000 in $1,000 principal amounts of convertible non-secured debentures ("Debentures"), which shall mature three years from the date of issuance of the Debentures (the "Maturity Date"), and issued a total of 2,500,000 common share purchase warrants with an exercise price of $0.15 for a period of three years. The Debentures shall bear a 12% annual simple interest calculated on the principal amount, with any accrued but unpaid interest under the Debentures due and payable on the anniversary of the Debenture in either cash or Common Shares (at the option of the Corporation) with the number of Common Shares being determined by using the 10 day volume-weighted average price of the Common Shares on the TSX Venture Exchange on that date that is five days prior to the anniversary date (subject to the approval of the TSX Venture Exchange). The Debentures may be converted by the holder at any time following the date of issuance at a price of $0.10 per share and the Debentures may be repaid partially, or in full, by the Corporation to any or all of the subscribers at any time without penalty.
Ventripoint Announces Completion of Analysis of Pulmonary Arterial Hypertension Clinical Data and Submission to FDA
ACCESSWIRE - Mon Oct 07, 6:23AM CDT
Clinical Trial Achieved all the Primary Endpoints for Heart Analysis
Ventripoint Announces Closing of Private Placement
Marketwire - Mon Jul 29, 5:49PM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSX VENTURE: VPT) (OTCQX: VPTDF) announces that it has completed the second closing of the second of its two previously announced non-brokered private placements.
University of Chicago Publishes First Results Using Ventripoint Heart Analysis System in Pulmonary Arterial Hypertension in Prestigous Medical Journal
Marketwire - Thu Jul 25, 6:01AM CDT
Ventripoint Diagnostics (TSX VENTURE: VPT)(OTCQX: VPTDF) is pleased to announce that the cardiology group from the University of Chicago, led by Dr. Roberto Lang, has published a paper entitled "Three-Dimensional Modeling of the Right Ventricle from Two-Dimensional Transthoracic Echocardiographic Images: Utility of Knowledge-Based Reconstruction(i) in Pulmonary Arterial Hypertension" in the Journal of the American Society of Echocardiography, Volume 26, Issue 8, Pages 860-867, August 2013.
